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SIGNIFICANCE
Linear IgA bullous dermatosis is a rare autoimmune di-
sease, marked by blistering, affecting both children and 
adults. It is characterized by auto-antibodies targeting va-
rious types of skin proteins. We retrospectively studied 54 
Italian patients with this disease. The auto-antibody tar-
gets were investigated using various blood tests (enzyme-
linked immunosorbent assay (ELISA), immunoblotting and 
indirect immunofluorescence on monkey oesophagus and 
salt-split skin). Indirect immunofluorescence on salt-split 
skin elicited the greatest diagnostic sensitivity. The most 
common target was LAD-1, followed by BP180-NC16A and 
BP230. Eighty-two percent of patients had circulating IgAs, 
and only 15% possessed circulating IgG auto-antibodies. 
Combined serological tests supported the diagnosis of li-
near IgA bullous disease.
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Linear immunoglobulin A (IgA) bullous dermatosis 
(LABD) is characterized by the presence of multiple 
IgA autoantibodies, and a comparatively lesser num-
ber of IgG antibodies, directed against different hemi-
desmosomal antigens. The main autoantigens are 
LAD-1, LABD-97, BP180 and BP230, type VII collagen 
and laminin 332. The serology of 54 Italian patients 
with LABD was studied retrospectively using enzyme-
linked immunosorbent assay (ELISA), immunoblotting 
assay, and indirect immunofluorescence on monkey 
oesophagus and salt-split skin. Among these, indirect 
immunofluorescence of salt-split skin elicits the grea-
test sensitivity. Sixty-three percent of the sera were 
observed to be positive, with a lamina lucida pattern 
observed in 48%, a sub-lamina densa pattern in 2% 
and a mixed pattern in 13% of cases. IgA reactivity to 
LAD-1 on immunoblotting was found in 52% of sera, to 
BP180-NC16A by ELISA in 32% and to BP230 in 26%. 
Only 17% of patients had circulating IgG autoantibo-
dies. LAD-1 was determined to be a major autoantigen 
of the lamina lucida subtype. Combined serological as-
says demonstrated a high sensitivity (82%), sugges-
ting that this approach could support diagnosis when 
a biopsy is not feasible or direct immunofluorescence 
results are negative.
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Linear IgA bullous dermatosis (LABD) is an IgA-mediated autoimmune bullous disorder occurring in 
adults and children, characterized by sub-epidermal blis-
ters and linear deposits of IgA at the basement membrane 
zone (BMZ) (1). Compared with other immunobullous 
diseases, LABD is immunologically a heterogeneous 
disease with pathogenic IgA autoantibodies against 
different hemidesmosomal antigens (2). Researchers 
have identified multiple targets over years of research, 
including collagen VII (3–5), laminin 332 (6), an un-
identified 285-kDa protein (7), bullous pemphigoid 230 
kDa antigen (BP230) (8), bullous pemphigoid 180 kDa 
antigen (BP180) (collagen XVII) (8), a 120-kDa protein 
(linear IgA disease-1 antigen; LAD-1) (9–11) and a 
97-kDa protein (LABD-97) (12–14) (Fig. 1A). The last 
2 antigens were subsequently denoted as parts of the 
extracellular domain of BP180 ectodomain (10, 15–18). 
BP180 is a hemidesmosomal type II transmembrane 
protein comprising an intracytoplasmic domain (NC16C 
domain), a transmembrane domain (NC16B domain), 
and an extracellular region with 15 collagenous domains 
and 16 non-collagenous domains (NC16A to NC1) (Fig. 
1A) (19). The NC16A domain is the main epitope in bul-
lous pemphigoid. BP180 can be cleaved physiologically 
within the NC16A domain by ADAM9/17 (16, 20) or 
pathologically by plasmin (21) and neutrophil elastase 
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Fig. 1. (A) Schematic representation of human BP180 and its fragments LAD-1 and linear IgA bullous dermatosis (LABD)-97. (B) The shed ectodomain 
of BP180 (LAD-1) is recognized by IgG and IgA autoantibodies as a 120-kDa polypeptide. Anti-BP180-positive bullous pemphigoid serum bind 120-kDa 
polypeptide by IgG (lane 1), molecular weight marker (lane 2), an anti-BP180 positive LABD serum bind 120-kDa polypeptide by IgA (lane 3), healthy 
volunteer serum does not bind 120-kDa polypeptide by IgA (lane 4); (C) IgA reactivity to LAD-1 (120 kDa) detected by immunoblotting: lane 1, healthy 
volunteer serum; lane 2, LABD control serum; lanes 3–7, LABD patient sera from the present study.
ding to LAD-1 (Fig. 1B). Further processing of LAD-1 
within the carboxyl-terminal NC4 domain yields a 97-
kDa fragment corresponding to LABD-97 (23, 24). 
LABD differs from bullous pemphigoid, in which 
IgG autoantibodies preferentially target other parts of 
BP180 (25, 26). Furthermore, it has been shown that 
IgA autoantibodies from subsets of patients with LABD 
recognize epitopes within the NC16A region (27, 28).
LABD displays 2 major binding patterns of IgA auto-
antibodies in indirect immunofluorescence of salt-split 
skin (IIF-SSS) and in immuno-electron microscopy. The 
majority of the LABD sera IgA react with the epidermal 
side of IIF-SSS, corresponding to the lamina lucida type 
sera, while a fewer number of IgA react with the dermal 
side of IIF-SSS, corresponding to the sub-lamina densa 
type sera (29, 30). A limited number of IgA elicit mixed 
reactivity to both locations. The type VII collagen in 
anchoring fibrils was determined to be the primary target 
of IgA antibodies from patients with sub-lamina densa 
type of LABD (4, 5, 31). In contrast, most patients with 
lamina lucida type LABD have IgA autoantibodies tar-
geting LABD-97 (12–14) and LAD-1 (9, 10). 
The autoimmune heterogeneity considers both targeted 
antigens as well as the involved Ig class. Apart from auto-
reactive IgAs, IgGs were also reported to be associated 
with LABD, which are detected as linear deposits at the 
BMZ in direct immunofluorescence (DIF) and detected 
in patients’ sera in IB testing or by enzyme-linked im-
munosorbent assay (ELISA) (6). 
The present retrospective study characterized the 
humoral immune response of 54 Italian patients with 
LABD using standard approaches, such as IIF-SSS and 
commercial and adapted ELISAs. In addition, this study 
suggests that LAD-1 is the major antigen LAD-1 as a 
major auto-antigen in Caucasian patients affected by the 
lamina lucida type LABD. 
MATERIALS AND METHODS
Patients
Sera were collected from 54 patients with LABD, including 
children and adults from different Italian clinical centres (Milan, 
Pavia, Genoa, Florence and Rome) between 2012 and 2017, for 
retrospective study. All patients typically demonstrated clinical, 
histopathological and immunopathological features of LABD 
(32): (i) vesicular or bullous eruption involving skin and mucous 
membranes; (ii) sub-epidermal blisters infiltrated predominantly 
by neutrophils detected in lesion biopsies; (iii) linear IgA-deposit 
pattern at the BMZ detected by DIF. Patients with both IgA and 
IgG deposits at the BMZ detected by DIF were excluded. Due to 
the retrospective design of the study, information on drug-induce 
LABDs was not available for all patients.
Indirect immunofluorescence
IIF was performed on monkey oesophagus (MO) samples using 
commercial slides (BioSystems S.A. Barcelona, Spain). IIF-SSS 
was performed using a commercial kit (Immco Diagnostics, NY, 
USA). All sera were diluted in the ration 1:20 with phosphate-
buffered saline (PBS). The slides were incubated with the diluted 
sera for 30 min. After washing in PBS, the slides were coated with 
fluorescein isothiocyanate-conjugated goat anti-human IgA or IgG 
(Kallestad Diagnostic, Chaska, MN, USA) for 30 min. Following 
a further PBS wash, the slides were mounted in buffered glycerine 
and examined under a fluorescence microscope (Leitz, Wetzlar, 
Germany). An IIF titre greater than 1:40 was considered positive.
Enzyme-linked immunosorbent assay for IgG and IgA detection
LABD IgG autoantibodies against BP180-NC16A and BP230 were 
characterized using commercial ELISA kit (MBL Co, Nagoya, 
Japan), according to the manufacturer’s protocol. To compare the 
results obtained from different plates, optical densities (ODs) of 
the test samples were adjusted according to positive and negative 
control samples supplied in each kit. The protocol had been mo-
dified to an extent for the detection of IgA autoantibodies against 
BP180 and BP230. Briefly, BP180 and BP230 microwell strips 
were incubated with LABD patient sera diluted 50 times and 
appropriate control sera. After washing, the bound antibodies were 
detected using 10.000-fold diluted HRP-conjugated anti-human 
IgA antibody (Sigma-Aldrich, St Louis, MO, USA). Colour 
development was achieved using 3,3’,5,5’-tetramethylbenzidine 
(Sigma) and after the reaction ceased, OD was measured at 450 
nm with the correlation wavelength set at 620 nm using a micro-
plate reader (Bio-Rad Laboratories Inc., Hercules, CA, USA). The 
cut-off value was determined to be the mean OD measured in a 
cohort of serum samples collected from 30 healthy volunteers and 
3 standard deviations.
LAD-1 preparation and immunoblotting analysis
LAD-1, the 120-KDa soluble ectodomain of BP180, was isolated 
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Table I. Immunological test results in 54 patients with linear IgA 
bullous dermatosis (LABD)
Immunological test n (%)
Indirect immunofluorescence (basement membrane zone), IgA
Monkey oesophagus 8 (15)
Indirect immunofluorescence-salt-split skin, IgA
Overall indirect immunofluorescence-salt-split skin IgA positive 34 (63)
Split skin exclusively epidermal side (lamina lucida) 26 (48)
Split skin exclusively dermal side (sub-lamina densa) 1 (2)
Split skin both sides 7 (13)
Indirect immunofluorescence (basement membrane zone), IgG
Monkey oesophagus 0 
Split skin exclusively epidermal side 1 (2) 
Split skin exclusively dermal side 0
Split skin both sides 0
Immunoblotting, IgA
LAD-1 (120kDa) 28 (52) 
Enzyme-linked immunosorbent assay, IgA
BP180-NC16A 17 (32)
BP230 14 (26)
Enzyme-linked immunosorbent assay, IgG
BP180-NC16A 3 (6)
BP230 5 (9)
Table II. IgA reactivity profile in 34 indirect immunofluorescence- 












(n = 7) 
n (%)
Immunoblotting, IgA 
LAD-1(120kDa) 19 (73) 0 3 (43 
ELISA, IgA
BP180-NC16A 10 (38) 0 1 (14)
BP230 10 (38) 0 0
Combined - reactivity profile
LAD-1+BP180+BP230 5 (1) 0 0
LAD-1 +BP180 1 (4) 0 1 (13)
LAD-1 +BP230 1 (3.7) 0 0
human epidermis). Keratinocytes were grown at confluence and 
shed ectodomain of BP180 released in the medium was precipi-
tated by the addition of ammonium sulphate (30% saturated solu-
tion) and incubated overnight at 4°C. Precipitates were collected, 
re-suspended in 25 mmol/l Tris-HCL, pH 7.8, 65 mmol/l NaCl and 
5 mmol/LEDTA and dialysed against the same buffer overnight 
at 4°C. LAD-1 was electrophoresed on a 6% polyacrylamide gel 
in reducing conditions. 
Immunoreactivity was detected after transfer to polyvinylidene 
difluoride membrane (Immobilon-P, Millipore Corporation, Bil-
lerica, MA, USA), by incubation with a 1:20 dilution of patient 
or control sera, followed by incubation with alkaline phosphatase-
labelled secondary antibodies against IgA.
RESULTS
Study population
Serum samples were collected from 54 patients with 
LABD (12 children and 42 adults), 30 females and 24 
males, with overall mean age 41 ± 31 years (age range 
1–93 years). 
Indirect immunofluorescence results
Presence of IgA at the BMZ was detected in 8 out of 54 
(15%) serum samples from LABD patients, as tested 
by IIF on MO, while 34/54 (63%) serum samples from 
LABD patients were IgA-positive, as tested by IIF-SSS 
on human skin (Table I). In particular, 26/54 (48%), 1/54 
(2%) and 7/54 (13%) serum samples were determined to 
have lamina lucida, sub-lamina densa and mixed patterns, 
respectively (Table I). Considering adults and children 
individually: serum samples collected from 6/12 (50%) 
children and 28/42 (67%) adults reacted with IIF-SSS.
With regards to IgG, none of the serum samples reacted 
with IIF on MO, while 1/54 (2%) serum samples (which 
was extracted from an adult) reacted to the epidermal 
side of IIF-SSS on human skin. 
IgA reactivity profile
Overall, IB results indicated IgA reactivity to LAD-1 
in 28/54 serum samples (52%) (Table I, Fig. 1C). Anti-
LAD-1 IgA were detected by IB in 8/12 (67%) serum 
samples from children and from 20/42 (48%) serum 
samples adults. BP180-NC16A ELISA results were po-
sitive in 17/54 patients (32%) and BP230 ELISA results 
were positive in 14/54 patients (26%) (Table I). 
Considering the IIF-SSS pattern groups, serum samp-
les from patients with lamina lucida binding pattern had 
variable reactivity to different epidermal antigens, as 
shown in Table II. Some of the sera samples reacted 
with multiple epidermal antigens (Table II). Altogether, 
IgA from 24/26 (92%) samples binding to lamina lucida 
reacted with at least 1 of the epidermal antigens studied. 
IgG reactivity profile
ELISA with BP180-NC16A and BP230 were positive for 
3/54 (6%) and 5/54 patients (9%), respectively (Table I). 
Overall, circulating IgG antibodies anti-BP180-NC16A 
and/or anti-BP230 detected by ELISA were detected in 
9/54 (17%) serum samples, while the total number of 
serum samples with IgG autoantibodies detected either 
by DIF, IIF-SSS or ELISA were 7/54 (13%).
DISCUSSION
These results confirm the heterogeneity of IgA auto-
antibody (autoAbs) targets in LABD. The predominant Ig 
class auto-antibody in the present cohort of patients with 
LABD was IgA, whereas IgG was present in only 22% of 
patients. Auto-reactive IgAs in serum samples primarily 
targeted LAD-1, while targeting BP180-NC16A and 
BP230 to a lesser extent. 
The processed extracellular part of BP180 represents 
the primary antigenic stimulus in LABD, indicating 
that the processing induces neo-epitope formation (33). 
Extracellular regions of BP180 produced by removal of 
intra-cytoplasmic and transmembrane domains were re-
ported to be recognized by 83% of LABD serum samples 
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soluble ectodomain more efficiently than the full-length 
protein in patients with LABD; 50% of the adult LABD 
serum samples and 100% of child LABD serum samples 
recognized this target (11). Likewise, in our experiments, 
48% of adult LABD serum samples and 67% of child 
LABD serum samples reacted with LAD-1. In line with 
previous study, serum samples from children with LABD 
seem to particularly react with LAD-1 in comparison 
with adults; this finding could suggest a major role of 
neo-epitopes present in the LAD-1 antigen in the disease 
pathogenesis in children. However, due to the low num-
ber of patients in our cohort (8 patients) and in the cohort 
from Schumann’s study (7 patients), no conclusion can 
be drawn. This issue should be investigated further on a 
larger cohort. In the present study, approximately 50% of 
the patients were positive for anti-LAD-1 IgA, and this 
proportion increased to 73% when only lamina lucida 
type patients were considered. Moreover, there was a 
strong correlation (90%) between lamina lucida positive 
sera and reactivity to BP180 (both LAD-1 and NC16A) 
and BP230. IgA positive against BP180-NC16A was 
detected consistently in a significant number (38%) of 
patients, which is in line with previous reports (6, 27, 28, 
34). Notably, only 50% of these patients had targeted both 
LAD-1 and BP180-NC16A, while 50% exclusively tar-
geted BP180-NC16A. Also, as anticipated, most patients 
positive for LAD-1 IgA (detected by IB) were negative 
for BP180-NC16A IgA (detected by ELISA). Notably, 
autoAbs directed against BP230 were more frequently 
detected in patients with LABD when BP180 autoAbs 
were also present. This association could depend on an 
intermolecular epitope spreading phenomenon (35, 36). 
Specifically, the pathological progression could induce 
damage in epithelial cells and result in abnormal expo-
sure of the intracellular BP230, inducing the production 
of autoAbs (35). Undoubtedly, IB for 285 kDa antigen, 
LABD-97, full-length BP180 and type VII collagen 
might have yielded significant results; however, due to 
economic and technical limitations these tests were not 
conducted.
The concentration of circulating IgGs reactive to BMZ 
antigens was significantly low (17%). This is in sharp 
contrast with the results reported recently by Ohata et 
al., in which positive circulating IgG autoantibodies 
were detected either by IIF, IB or ELISA in 53% of their 
serum samples (6). The current study probably observed 
lower rates of auto-reactive circulating IgGs, as unlike 
the protocol adopted by Ohata et al., we did not test for 
IgGs directed against a wider variety of autoantigens. 
Considering LABD and BP to be opposite ends of the 
same spectrum, as suggested by Ohata et al. (6), might be 
inaccurate; however, these 2 diseases are overlap signi-
ficantly in terms of clinical and serological aspects (37).
The higher positivity rates of IIF-SSS compared with 
IIF on MO confirmed the higher sensitivity of IIF-SSS 
in detecting auto-reactive IgAs. Our results confirm that 
the lamina lucida type is the most frequent variant of 
LABD. This is in line with a previous report suggesting 
that IgA reactivity is more prevalent on the epidermal 
end than on the dermal end of IIF-SSS (6). 
The present study denotes that serological diagnosis of 
LABD patients can be performed using different assays 
for detection of IgG and IgA circulating autoantibodies 
(IIF, IB on LAD-1, BP180 and BP230 ELISAs). Nota-
bly, the combined sensitivity allows detection of auto-
antibodies in 83% of patients (45/54). Specifically, the 
most efficient process hierarchy involves DIF, followed 
by IIF-SSS as the most sensitive approach, followed by 
IB on LAD-1 and ELISA on IgA BP180, and IgA BP230 
ELISA performed in case of negative results (which in 
one case was the only positive serological test). Notably, 
none of the LABD serum samples that resulted negative 
for circulating IgA antibodies in IIF, IB for LAD-1 or 
ELISA for BP180, were positive for IgG ELISAs.
This study has certain limitations; it focused specifi-
cally on the epidermal antigens targeted in LADB, and 
only a limited number of paediatric patients were studied. 
Conclusion
LABD is characterized by a heterogeneous humoral 
response, largely comprising IgA auto-antibodies and a 
lesser number of IgG autoantibodies. It is yet to be esta-
blished if these auto-antibodies elicit pathogenicity. Se-
veral antigens of the BMZ are targeted by auto-antibodies 
in LABD. LAD-1 is a major auto-antigen of the lamina 
lucida subtype, particularly in children. DIF remains 
the most preferred diagnostic method for detection of 
LABD. However, the combination of several serological 
assays could an important approach to support diagnosis, 
especially in cases in which a biopsy is not feasible or 
the DIF results are negative.
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